Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the development, manufacturing & sale of pharmaceutical products and services& trading of commodities and renting of properties. The Company manufactures and markets more than 200 pharmaceutical formulation products in various dosage forms, like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections and Dry Vial injections, Dry Syrups, Ointments and Inhalers. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Albendazole Oral Suspension USP 100mg, Cetirizine Oral Solution BP, Clotrimazole Cream USP, Compound Benzoic Acid Ointment BP, and others.
Syncom Formulations (India) Ltd FAQs
How to Buy Syncom Formulations (India) Ltd Share?
To purchase Syncom Formulations (India) Ltd shares, you can open a Demat & Trading account through a broker or financial institution. Once your account is set up and funded, search for Syncom Formulations (India) Ltd (ticker symbol: SYNCOMF) on the trading platform provided by your broker and purchase the shares.
The stock price of Syncom Formulations (India) Ltd as of 07 Oct 2025 is ₹15.95
What is the Market Cap of Syncom Formulations (India) Ltd?
Market capitalisation represents the total market value of a company's outstanding shares. As of 07 Oct 2025, Syncom Formulations (India) Ltd (ticker symbol: SYNCOMF) has a market capitalisation of approximately ₹15,90,00,00,000.00
What is the PE and PB ratio of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd Ltd's price-to-book ratio as of 07 Oct 2025 is 4.38, reflecting the market's valuation compared to its asset value. As of 07 Oct 2025, the trailing twelve months P/E (price-to-earnings) ratio is 30.09, indicating the market values the company at around ₹30.09 for every ₹1 of earnings
What is the 52 Week High and Low of Syncom Formulations (India) Ltd Share?
Syncom Formulations (India) Ltd Ltd (SYNCOMF) hit its 52-week high at ₹23.87, and its 52-week low at ₹14.10.